Compliance position

We say no when no is the right answer.

PeptiOEM serves qualified B2B and research buyers — med spas, longevity clinics, 503A compounding pharmacies, OEM brand owners and research labs. We do not sell to consumers, and we do not supply restricted use cases. The GLP-1 family is OUS-only under the FDA's 2026 503B bulks proposal.

Buyer policy

Two clear lines for who we sell to.

Inquiries from these contexts get a fast, structured reply. Everything else gets a polite redirect.

Allowed buyer contexts

Med spas and aesthetic / wellness clinics
Longevity and integrative-medicine clinics
503A compounding pharmacies for individual prescriptions
Research labs (university, hospital, private)
Private-label and OEM brand owners
OUS distributors for the GLP-1 family

Not supplied

Consumer-direct medical advice, treatment claims, dosing or administration guidance
503B outsourcing facilities for compounds covered by the FDA's 2026 bulks list proposal
Any buyer who cannot identify a qualified B2B or research context
US-bound GLP-1 supply intended for large-scale compounding under the proposed 503B restriction

FDA framework

503A and 503B — what they mean for peptide supply.

503A pharmacies	Traditional state-licensed compounding pharmacies that fill individual prescriptions for identified patients. PeptiOEM supplies 503A pharmacies with context-specific documentation for compounds outside the FDA's 2026 503B bulks restriction.
503B outsourcing facilities	Federally registered facilities that compound from bulk substances on the 503B bulks list. On 2026-04-30 the FDA proposed removing GLP-1 medications (semaglutide, tirzepatide, liraglutide) from this list. Comment period closes 2026-06-29. PeptiOEM does not supply 503B facilities for GLP-1 compounds while this proposal is pending or finalized.
Engine 1 (non-GLP-1)	Worldwide supply for med spas, longevity clinics, 503A pharmacies, research labs and OEM brand owners. Repair, growth-hormone axis, longevity, beauty, cognitive and NAD+ compounds.
Engine 2 (GLP-1 family)	OUS (non-US) distribution markets, research, and private-label brand evaluation only. Destination country and buyer track confirmed before quoting.

What we do not provide

Hard limits, written plainly.

No medical advice

No diagnosis, treatment claim, dosing, administration guidance or therapeutic implication. Clinical decisions belong with licensed clinicians.

No consumer sales

PeptiOEM is B2B and research only. We do not sell to consumers and do not market to consumers.

No restricted supply

No supply to use cases restricted by the FDA's 2026 503B bulks list proposal or other applicable regulatory frameworks.

Read the GLP-1 update

A clearer view of where US GLP-1 supply is heading.

The 2026-04-30 FDA proposal, comment-period deadline, OUS opportunities, and what it means for med spas, 503A pharmacies, and brand owners.

Read the GLP-1 2026 update →